PT Indofarma Tbk (ISX:INAF) LT-Debt-to-Total-Asset: 0.93 (As of Mar. 2026)

What is PT Indofarma Tbk LT-Debt-to-Total-Asset?

PT Indofarma Tbk ISX:INAF 8 LT-Debt-to-Total-Asset is 0.93 as of Mar. 2026. GuruFocus rates ISX:INAF with a GF Score™ of 8/100 and a GF Value™ of Rp176.99. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PT Indofarma Tbk's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.93.

PT Indofarma Tbk's long-term debt to total assets ratio increased from Mar. 2025 (0.38) to Mar. 2026 (0.93). It may suggest that PT Indofarma Tbk is progressively becoming more dependent on debt to grow their business.

PT Indofarma Tbk (ISX:INAF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PT Indofarma Tbk LT-Debt-to-Total-Asset Related Terms

PT Indofarma Tbk LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for PT Indofarma Tbk's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk LT-Debt-to-Total-Asset Chart

PT Indofarma Tbk Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.20

0.29

0.39

0.35

0.85

PT Indofarma Tbk Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.38	0.39	0.37	0.85	0.93

8GF Score

PT Indofarma Tbk ISX:INAF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PT Indofarma Tbk LT-Debt-to-Total-Asset Calculation

PT Indofarma Tbk's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	455002.552	/	535988.243
	=	0.85

PT Indofarma Tbk's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	455002.552	/	489667.151
	=	0.93

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.93 mean?

PT Indofarma Tbk (ISX:INAF) has a LT-Debt-to-Total-Asset of 0.93 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PT Indofarma Tbk and its competitors.

Is PT Indofarma Tbk's LT-Debt-to-Total-Asset too high?

PT Indofarma Tbk's current LT-Debt-to-Total-Asset is 0.93. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.

How does PT Indofarma Tbk's LT-Debt-to-Total-Asset compare to ZTS and VTRS?

PT Indofarma Tbk's LT-Debt-to-Total-Asset of 0.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current LT-Debt-to-Total-Asset is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PT Indofarma Tbk stock overvalued right now?

PT Indofarma Tbk (ISX:INAF) has a current LT-Debt-to-Total-Asset of 0.93. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.93. PT Indofarma Tbk's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current LT-Debt-to-Total-Asset is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

LT-Debt-to-Total-Asset: 0.93
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
GF Score™: 8/100 with 5 warning signs

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Indofarma Tbk Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ISX:MERK ISX:DVLA ISX:PEHA ISX:PYFA ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530

Website https://www.indofarma.id

PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.

8GF Score

Get the complete analysis for ISX:INAF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00

Price

Rp176.99

GF Value

View ISX:INAF Analysis

See LT-Debt-to-Total-Asset data for all stocks →